Communicators

CRESO PHARMA NOW TRADING ON THE FRANKFURT STOCK EXCHANGE; APPOINTS DGWA AS GERMAN CORPORATE ADVISOR

17. June 2018, Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to announce its listing on the Frankfurt Stock Exchange following the successful, revenue-generating dual product launch of cannaQIX® and anibidiol® and initial sales orders in Europe’s Benelux region.

In response to growing interest from European investors, Creso has appointed Deutsche Gesellschaft für Wertpapieranalyse GmbH ("DGWA"), a German Institute for asset management and a boutique European investment and financial markets consulting firm based in Frankfurt, Germany. The engagement is in respect to Creso’s European investor relations strategy; to position the Company in the German speaking media environment and to assist the Company in its relations with German retail and institutional investors, as well as the strategy and management of the Frankfurt Stock Exchange listing.

European investors can trade the Company’s ordinary shares under the stock code: “1X8” on the Frankfurt Stock Exchange.

Commenting on the listing, Creso’s CEO Dr Miri Halperin Wernli said:

“Given our headquarters in Switzerland and our dominant European operations, we were pleased to offer European investors the ability to invest in Creso. This was in response to strong investor appetite out of Europe and the Frankfurt exchange. We have already seen success from our products in Europe and anticipate further opportunities for growth and advancement in the region.”

Following the engagement of DGWA, Creso anticipates an increase in the stock's liquidity levels and greater Company exposure leading to a broader shareholder base. In turn, the exposure is expected to increase the Company’s profile and promote Creso’s operational activities in the European region. 

Creso has recently expanded sales of its human and animal health products across Europe with cannaQIX® now being sold in the Benelux region and in the UK and initial sales orders placed.

Listing on the Frankfurt Stock Exchange is part of Creso’s broader aim to cement its presence in all key global markets. Creso announced in June 2018 the appointment of Mr John Griese as Chief Operating Officer for the Americas to help establish and grow the Company’s presence in North America.

About DGWA

https://dgwa.org

Deutsche Gesellschaft für Wertpapieranalyse GmbH ("DGWA") is a German Institute for asset management and a boutique European investment and financial markets consulting firm based in Frankfurt, Germany. The management team have a 25-year track record in trading, investing and analysing SME’s around the world. DGWA has been involved in over 250 IPO’s, financings, bond issues, dual listings and corporate finance transactions as well as corresponding road shows and awareness campaigns.

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.  It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.  It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Investor Queries

EverBlu Capital

P: +61 2 8249 0000

E: info@everblucapital.com

Here is the link to the presentation: https://www.irw-press.com/tl_files/pdf/CresoCorporatePresentationJuly2018.pdf